Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment

被引:197
作者
Crettol, S
Déglon, JJ
Besson, J
Croquette-Krokkar, M
Gothuey, I
Hämmig, R
Monnat, M
Hüttemann, H
Baumann, P
Eap, CB [1 ]
机构
[1] Univ Lausanne, Hop Cery, Ctr Neurosci Psychiat, Dept Psychiat Adulte,Unite Biochim & Psychopharma, CH-1008 Lausanne, Switzerland
[2] Fdn Phenix, Geneva, Switzerland
[3] CHU Vaudois, Ctr St Martin, Unite Toxicodependance, Dept Psychiat, CH-1011 Lausanne, Switzerland
[4] Hop Cantonal Univ Geneva, Dept Psychiat, Montreux, Switzerland
[5] Unite Ambulatoire Specialisee, Montreux, Switzerland
[6] Univ Bern, Psychiat Dienste Bern, Bern, Switzerland
关键词
D O I
10.1016/j.clpt.2005.08.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective: Recent in vitro studies have suggested an important role of cytochrome P450 (CYP) 2B6 and CYP2C19 in methadone metabolism. We aimed to determine the influence of CYP2B6, CYP2C9, and CYP2C19 genetic polymorphism on methadone pharmacokinetics and on the response to treatment. Methods. We included 209 patients in methadone maintenance treatment on the basis of their response to treatment and their daily methadone dose. Patients were genotyped for CYP2B6, CYP2C9, and CYP2C19. Steady-state trough and peak (R)-, (S)-, and (RS)-plasma levels and peak-to-trough plasma level ratios were measured. Results: CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng (.) kg/mL (.) mg for the noncarriers of allele *6, heterozygous carriers, and homozygous carriers (*6/*6), respectively (P = .0004). CYP2C9 and CYP2C19 genotypes do not influence methadone plasma levels. Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng (.) kg/mL (.) mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)]. Conclusion: Although CYP2B6 influences (S)-methadone plasma levels, given that only (R)-methadone contributes to the opioid effect of this drug, a major influence of CYP2B6 genotype on response to treatment is unlikely and has not been shown in this study. Lower plasma levels of methadone in nonresponders, suggesting a higher clearance, and higher peak-to-trough ratios, suggesting a shorter elimination half-life, are in agreement with the usual clinical measures taken for such patients, which are to increase methadone dosages and to split the daily dose into several intakes.
引用
收藏
页码:593 / 604
页数:12
相关论文
共 46 条
  • [1] A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation
    Ariyoshi, N
    Miyazaki, M
    Toide, K
    Sawamura, Y
    Kamataki, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (05) : 1256 - 1260
  • [2] Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers
    Begré, S
    von Bardeleben, U
    Ladewig, D
    Jaquet-Rochat, S
    Cosendai-Savary, L
    Golay, KP
    Kosel, M
    Baumann, P
    Eap, CB
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (02) : 211 - 215
  • [3] Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone
    Benmebarek, M
    Devaud, C
    Gex-Fabry, M
    Golay, KP
    Brogli, C
    Baumann, P
    Gravier, B
    Eap, CB
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (01) : 55 - 63
  • [4] CHANG TKH, 1993, CANCER RES, V53, P5629
  • [5] Code EL, 1997, DRUG METAB DISPOS, V25, P985
  • [6] Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
    Colombo, S
    Soranzo, N
    Rotger, M
    Sprenger, R
    Bleiber, G
    Furrer, H
    Buclin, T
    Goldstein, D
    Décosterd, L
    Telenti, A
    [J]. PHARMACOGENETICS AND GENOMICS, 2005, 15 (09) : 599 - 608
  • [7] Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships
    Dyer, KR
    Foster, DJR
    White, JM
    Somogyi, AA
    Menelaou, A
    Bochner, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (06) : 685 - 694
  • [8] The relationship between mood state and plasma methadone concentration in maintenance patients
    Dyer, KR
    White, JM
    Foster, DJR
    Bochner, H
    Menelaou, A
    Somogyi, AA
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (01) : 78 - 84
  • [9] Interindividual variability of the clinical pharmacokinetics of methadone - Implications for the treatment of opioid dependence
    Eap, CB
    Buclin, T
    Baumann, P
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (14) : 1153 - 1193
  • [10] Cytochrome P450 2D6 genotype and methadone steady-state concentrations
    Eap, CB
    Broly, F
    Mino, A
    Hämmig, R
    Déglon, JJ
    Uehlinger, C
    Meili, D
    Chevalley, AF
    Bertschy, G
    Zullino, D
    Kosel, M
    Preisig, M
    Baumann, P
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (02) : 229 - 234